Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles (EV)-Exosomes: Diagnostics, Delivery and Therapeutics

Johnathon Anderson's Biography

Johnathon Anderson, Assistant Professor, University of California-Davis

Dr. Anderson performed his Ph.D. and postdoctoral training at the University of California Davis investigating the composition and functional properties of extracellular vesicles derived from mesenchymal stromal cells. Following his faculty appointment at UC Davis in the Department of Otolaryngology, he expanded his work into the investigation of head and neck cancer cells and cancer-associated fibroblasts, as a KL2 fellow. Currently, his group is interested in the glycosylational composition and functional properties of mesenchymal stromal cells and cancer-associated fibroblasts, particularly their ability to regulate immune responses.

Johnathon Anderson Image

Extracellular Vesicle Glycosylation

Friday, 26 February 2021 at 10:30

Add to Calendar ▼2021-02-26 10:30:002021-02-26 11:30:00Europe/LondonExtracellular Vesicle GlycosylationExtracellular Vesicles (EV)-Exosomes: Diagnostics, Delivery and Therapeutics in Virtual ConferenceVirtual

Up to 50% of the proteins encoded in the human genome are predicted to contain glycosylation sites. Aberrant glycosylation is a hallmark of several diseases, including many types of cancer from different origins. Although the functional significance of such patterns of glycan expression and presentation are not yet well characterized, tumor growth, metastases and immunoregulation have all been associated with such abnormal displays of glycosylation within the tumor microenvironment. Our group is interested in understanding glycosylation dynamics in the context of cancer-associated fibroblasts (CAFs), and mesenchymal stromal cells (MSCs), which serve as a source of CAFs in some types of cancer. One of the most remarkable changes in cancer glycosylation is the aberrant expression of sialic acid–bearing glycans called sialoglycans. Cells within the tumor bed are often covered with a dense layer of sialoglycans which have emerged in recent years as potent immune modulators that promote tumor immune evasion. Sialoglycans serve as the cognate ligands for a family of immune checkpoint receptors called sialic acid–binding immunoglobulin-like lectins (Siglecs), which are expressed by various populations of leukocytes. Preclinical studies have shown that tumor associated sialoglycans negatively influence immune cell function by interacting with the immune-inhibitory Siglec family members. Our group is interested in how sialoglycan expression is regulated in MSCs and CAFs, and what functional role they may play in their derived extracellular vesicles.

Add to Calendar ▼2021-02-25 00:00:002021-02-26 00:00:00Europe/LondonExtracellular Vesicles (EV)-Exosomes: Diagnostics, Delivery and TherapeuticsExtracellular Vesicles (EV)-Exosomes: Diagnostics, Delivery and Therapeutics in Virtual ConferenceVirtual